Nabil Daoud
YOU?
Author Swipe
View article: Safety and Effectiveness of Emicizumab in People With Haemophilia A Enrolled in the ATHN 7 Haemophilia Natural History Study
Safety and Effectiveness of Emicizumab in People With Haemophilia A Enrolled in the ATHN 7 Haemophilia Natural History Study Open
Background The Natural History Study of the Safety, Effectiveness, and Practice of Treatment for People with Haemophilia (ATHN 7) monitors use of contemporary haemophilia therapies, including emicizumab, a bispecific antibody substituting …
View article: Assessing the impact of distance from primary hemophilia treatment center on annualized bleeding rates in people with inheritable bleeding disorders
Assessing the impact of distance from primary hemophilia treatment center on annualized bleeding rates in people with inheritable bleeding disorders Open
Introduction: Access to federally-supported hemophilia treatment centers (HTC) is critically important in people with inheritable bleeding disorders (PwBD). Distance to an HTC has been reported as a barrier to access to acute care for blee…
View article: Observational cohort study of long‐term outcomes of liver transplantation in haemophilia
Observational cohort study of long‐term outcomes of liver transplantation in haemophilia Open
Introduction Gene therapy is now a reality for individuals with haemophilia, yet little is known regarding the quality‐of‐life impact of factor correction. As few data exist, and recognizing the analogy to liver transplantation (OLTX), we …
View article: Quality of Life in Emicizumab-Treated People with Hemophilia A in the ATHN 7 Hemophilia Natural History Study - an Assessment of Baseline PROMIS®-29 Scores
Quality of Life in Emicizumab-Treated People with Hemophilia A in the ATHN 7 Hemophilia Natural History Study - an Assessment of Baseline PROMIS®-29 Scores Open
Background: People with hemophilia A (PwHA) experience frequent bleeding into joints, muscles and soft tissues due to a deficiency of factor (F)VIII, which has a substantial negative impact on their health-related quality of life (HRQoL). …
View article: PB0625 Emicizumab Prophylaxis in People with Hemophilia A Aged >50 Years withComorbidities:ExperienceFromtheATHN7Hemophilia Natural History Study
PB0625 Emicizumab Prophylaxis in People with Hemophilia A Aged >50 Years withComorbidities:ExperienceFromtheATHN7Hemophilia Natural History Study Open
2.0, -0.5), respectively.Mean (95% CI) change for weekly injection frequency and weekly factor consumption (international unit/kg) were -0.8 (-1.0, -0.7) and -5.7 (-10.7,-0.6),respectively (Figure 1). Conclusion(s):Switching to rFVIIIFc fr…
View article: Designing ATHN 7: Safety, effectiveness and practice of treatment of people with haemophilia in the United States through a natural history cohort study
Designing ATHN 7: Safety, effectiveness and practice of treatment of people with haemophilia in the United States through a natural history cohort study Open
Background Haemophilia A and B are X-linked inherited bleeding disorders, resulting in the deficiency of clotting factor VIII and IX, respectively. Since the introduction of recombinant clotting factor concentrates in the early 1990s, the …
View article: Virilizing adrenocortical oncocytoma in a toddler
Virilizing adrenocortical oncocytoma in a toddler Open
Functioning adrenocortical oncocytomas are extremely rare and most reported patients are 40–60 yr of age. To our knowledge, only 6 cases of functioning adrenocortical oncocytomas have been reported in childhood. We report a case of functio…
View article: Giant mesenteric lipoma: A case report and a review of the literature
Giant mesenteric lipoma: A case report and a review of the literature Open
Mesenteric lipoma is a rare benign tumor of mature fat cells. Although generally asymptomatic, it occasionally causes abdominal pain, ileus, and small bowel volvulus, depending on its location and size. A definitive diagnosis can be made b…